We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Vicki G. Norton, Ph.D.

Duane Morris LLP


Results 1 to 5 of 17
Most popular |Most recent

What Your Competitors Don’t Know Can Hurt You - The Supreme Court Rules that Secret Sales Can Trigger the On-Sale Bar Under the AIA

USA - January 24 2019 The Supreme Court of the United States recently affirmed the decision of the U.S. Court of Appeals for the Federal Circuit in Helsinn Healthcare v...

Jonathan Lourie, Moreshwar (Moru) B.Vaze, PH.D, Matthew C. Mousley.

FDA Publishes Redraft of 510(k) Third Party Review Program

USA - November 20 2018 Section 523 of the Federal Food, Drug, and Cosmetic (FD&C) Act codifies the 510(k) Third Party Review Program (3P Review Program), which authorizes...

Lisa W. Clark, Ryan Smith, Jennifer A. Kearns, Jiazhong (Jason) Luo, Ph.D., JOHANN YI-DER LIN, PH.D., Stephen M. Honig, Frederick R. Ball, Carolyn A. Alenci.

IP Protection and the Cannabis Industry: Strategies and Trends

USA - April 2 2018 Protection of intellectual property is a key element in any company's efforts to secure a competitive advantage. For companies in the cannabis space...

Gretchen L. Temeles, Ph.D., Christiane Schuman Campbell.

Ten Years Of MedImmune: How License Agreements Changed

USA - February 15 2017 A decade ago, the U.S. Supreme Court’s ruling in MedImmune LLC v. Genentech Inc.1 permitted patent licensees to seek declaratory judgments of patent...

Jonathan Lourie.

Alert: Drug and Device Developers Should Be Aware of the Expanded Access Policy Requirement under the 21st Century Cures Act.

USA - December 9 2016 With Congress's recent passage of the 21st Century Cures Act (the "Cures Act") by an overwhelming majority, and President Obama's anticipated...

Sandra G. Stoneman.